Latest Regulatory Milestones News

Cavalier Resources has secured all primary approvals needed to advance Stage 1 mining at its Crawford Gold Project near Leonora. The regulatory milestone shifts attention to funding, site preparation and the finalisation of mining arrangements with SSH Mining.

Vitrafy has added US blood network Versiti to its cryopreservation development programme, with the partnership focused on no-wash platelet preservation and regulatory verification. The deal strengthens the company’s institutional network, but initially generates no revenue and remains subject to US regulatory requirements.

Mesoblast has secured FDA approval to add a new potency assay to commercial release and stability testing for Ryoncil, its approved cell therapy for paediatric graft-versus-host disease. The regulatory decision supports tighter monitoring as manufacturing processes evolve, but the company disclosed no direct financial impact or clinical outcome data.

4DMedical delivered sharp growth in scans, sites and operating revenue as CT:VQ moved into commercial deployment across several global markets. But the company remains loss-making and its auditor issued a qualified opinion over the carrying value of goodwill and other intangible assets.

Lake Resources has reduced Kachi’s estimated capital cost by US$220 million and outlined a 25-year, 25,000-tonne-per-year operation. But the lithium developer still needs further funding, environmental approval, offtake and a final investment decision before construction can begin.

Elementos has materially strengthened its balance sheet while moving its Spanish Oropesa tin project closer to permitting, financing and a final investment decision. The annual report also highlights a doubling of Cleveland’s inferred tungsten resource, but both projects still require substantial capital and further approvals.

Telix will acquire ITM in a proposed US$1.65 billion deal that combines a commercial radioisotope supplier with Telix’s precision medicine and therapeutic pipeline. The transaction could give Telix greater supply-chain control and entry into a validated cancer treatment market, but it also brings dilution, integration risk and an unresolved FDA pathway for ITM-11.

CurveBeam AI has raised A$1.75 million through an oversubscribed SPP shortfall offer and placement, lifting its recent capital raised to A$7.36 million. The funds will support the HiRise China launch, product development, supply-chain preparation and working capital.

Memphasys has signed a three-year exclusive distribution agreement covering the Czech Republic, Slovakia and Kazakhstan, with minimum purchases worth approximately A$674,000. The deal expands Felix’s European footprint while adding dedicated commercial leadership in the region.

EBR Systems’ new Santa Clara manufacturing facility has entered the FDA’s pre-approval inspection process, marking a key regulatory step for its wireless cardiac pacing business. The company continues to expect approval by the end of 2026, but the inspection does not yet amount to clearance.

Vulcan Energy has secured a second lithium production licence for its Lionheart project in Germany, removing another regulatory milestone on the path to targeted production in 2028. The Ilka licence is initially valid for six years, leaving a future consolidation and extension process still to complete.

Barton Gold has secured approval for the environmental scope governing development studies at its Tunkillia gold and silver project in South Australia. The milestone moves the project towards a Mining Lease application, with updated resources, Ore Reserves and a pre-feasibility study targeted for the first quarter of 2027.